H.C. Wainwright lowered the firm’s price target on MacroGenics (MGNX) to $2 from $4 and keeps a Neutral rating on the shares. The firm says it has been a long time coming for discontinuing clinical development of vobra duo.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks